General Information of Disease (ID: DIS327VW)

Disease Name Substance abuse
Definition The use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed.
Disease Hierarchy
:
DIS327VW: Substance abuse
Disease Identifiers
MONDO ID
MONDO_0002491
MESH ID
D019966
UMLS CUI
C0740858
MedGen ID
152849
SNOMED CT ID
66214007

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 38 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CNR1 TT6OEDT Limited Biomarker [1]
DRD4 TTE0A2F moderate Genetic Variation [2]
ABAT TTT2LD9 Strong Biomarker [3]
ABCC4 TTUEAFL Strong Biomarker [4]
CD274 TT8ZLTI Strong Biomarker [4]
CFTR TTRLZHP Strong Biomarker [4]
CHRM2 TTYEG6Q Strong Biomarker [5]
CHRNA5 TTH2QRX Strong Biomarker [6]
CNP TT71P0H Strong Altered Expression [7]
CYP2D6 TTVG215 Strong Genetic Variation [8]
DRD2 TTEX248 Strong Genetic Variation [9]
DRD3 TT4C8EA Strong Genetic Variation [10]
DRD5 TTS2PH3 Strong Genetic Variation [11]
FHIT TTMS54D Strong Biomarker [4]
FKBP15 TT1XEQO Strong Biomarker [4]
GABRA2 TTBMV1G Strong Genetic Variation [12]
GRIA4 TTPJR0G Strong Biomarker [4]
GRIK2 TT0K5RG Strong Biomarker [4]
GRM2 TTXJ47W Strong Biomarker [13]
GRM5 TTHS256 Strong Biomarker [14]
GRM7 TT0I76D Strong Biomarker [4]
HTR2C TTWJBZ5 Strong Biomarker [15]
INSR TTCBFJO Strong Biomarker [4]
MAG TT9XFON Strong Altered Expression [7]
MKNK1 TTEZAUX Strong Biomarker [4]
NPY TT64REZ Strong Biomarker [16]
OPRD1 TT27RFC Strong Biomarker [4]
OPRK1 TTQW87Y Strong Posttranslational Modification [17]
OPRM1 TTKWM86 Strong Biomarker [18]
PDE10A TTJW4LU Strong Genetic Variation [19]
PDE1C TTW2HRK Strong Biomarker [4]
PLA2R1 TTHKW7D Strong Biomarker [4]
PRKCE TT57MT2 Strong Biomarker [4]
PRKCH TTONI0R Strong Biomarker [4]
SLC10A2 TTPI1M5 Strong Biomarker [4]
SLC22A3 TTG2UMS Strong Biomarker [20]
SLC6A3 TTVBI8W Strong Genetic Variation [21]
SLK TT8K4DE Strong Biomarker [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 38 DTT(s)
This Disease Is Related to 2 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC2A13 DT0NSKB Strong Biomarker [4]
SLC45A2 DTNCJAT Strong Biomarker [4]
------------------------------------------------------------------------------------
This Disease Is Related to 2 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
FAAH DEUM1EX Strong Biomarker [22]
MSRA DEU2ZBY Strong Biomarker [4]
------------------------------------------------------------------------------------
This Disease Is Related to 91 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ABLIM1 OTHXEK3E Strong Biomarker [4]
ADARB2 OTDJKS39 Strong Biomarker [4]
AFF3 OTR0705Z Strong Biomarker [4]
AGBL4 OTOX2H61 Strong Biomarker [4]
AKAP7 OT0L3PZ6 Strong Biomarker [4]
ANK3 OTJ3IRBP Strong Biomarker [23]
ANO4 OT8E2PMA Strong Biomarker [4]
APPL2 OT9S4C4K Strong Biomarker [4]
ASTN1 OT23FQIB Strong Genetic Variation [24]
ATP1B1 OTTO6ZP4 Strong Biomarker [4]
AZI2 OT61Q7Q8 Strong Biomarker [21]
BCAR3 OTPJ17M8 Strong Biomarker [4]
BPIFA2 OTLFSDZD Strong Biomarker [4]
BTBD8 OT3A3RD7 Strong Genetic Variation [25]
C19orf18 OTY38VMO Strong Biomarker [4]
C5orf63 OTKTZVBF Strong Biomarker [4]
CADPS2 OTV1FW0M Strong Biomarker [4]
CCDC91 OTLZNXDL Strong Biomarker [4]
CDCP1 OTD7RRWK Strong Biomarker [4]
CDH13 OTD2CYM5 Strong Biomarker [26]
CERS6 OTOP4GV1 Strong Biomarker [4]
CHCHD3 OT8BDECJ Strong Biomarker [4]
CHD1L OT7CZK7C Strong Biomarker [4]
COLEC12 OTIQTK9G Strong Biomarker [4]
CSMD1 OTIVDSC4 Strong Biomarker [4]
CSMD3 OTAT75SW Strong Biomarker [4]
CSRNP3 OTOANEHZ Strong Biomarker [4]
CSRP3 OTECBJMV Strong Biomarker [4]
CTNNA3 OT9Z0P1E Strong Biomarker [4]
CXCL14 OTM189TA Strong Biomarker [4]
DDX1 OT3U8FD0 Strong Biomarker [4]
DDX53 OTHK3EGZ Strong Genetic Variation [27]
DNAH8 OTGES2OU Strong Biomarker [4]
DNASE1L3 OTEUIMC2 Strong Biomarker [28]
DOCK1 OTCFV3ON Strong Biomarker [4]
DSCAM OTL7PRMK Strong Biomarker [4]
EHHADH OTBAAHL5 Strong Biomarker [4]
EIPR1 OTNQKNL3 Strong Biomarker [4]
EPB41 OTGCFPV8 Strong Biomarker [29]
ETV6 OTCZMG61 Strong Biomarker [4]
FAM184A OTAI8E9G Strong Biomarker [4]
FAM184B OTIHXYJC Strong Biomarker [4]
FARP1 OTL1EBTM Strong Biomarker [4]
FHOD3 OT1WUBQX Strong Biomarker [4]
FLOT2 OTZ0QR5L Strong Biomarker [30]
FRMD4A OTJDTIK2 Strong Biomarker [4]
GABRB3 OT80C3D4 Strong Biomarker [31]
GBA3 OT86XWU2 Strong Biomarker [4]
HOMER1 OTWFD3SI Strong Genetic Variation [32]
HOMER2 OT4JGKJF Strong Genetic Variation [32]
HSPA12A OTFOCDD6 Strong Biomarker [4]
KLF12 OTVH4KD4 Strong Biomarker [4]
LDLRAD3 OTYAKC55 Strong Biomarker [4]
LIMCH1 OTYPC4XA Strong Biomarker [4]
LRMDA OTIPNKTU Strong Biomarker [4]
MACROD2 OTNQCHC6 Strong Biomarker [4]
MPC1 OT6DYFUO Strong Biomarker [4]
MPP7 OT3G3HTZ Strong Biomarker [4]
MYO5C OTKLOCWZ Strong Biomarker [4]
MYO6 OTJQYRC7 Strong Biomarker [4]
NCS1 OT6JHAWM Strong Altered Expression [33]
NME7 OTYMBK3Q Strong Biomarker [4]
NPS OTEG25A2 Strong Biomarker [34]
NRCAM OT80HHQ2 Strong Biomarker [35]
NRXN3 OTJ0I7HJ Strong Biomarker [4]
OLIG2 OTMCN6D3 Strong Altered Expression [7]
OR51E1 OTB7Q65H Strong Biomarker [4]
PACS1 OT9TMQL3 Strong Biomarker [4]
PARP9 OT7K4494 Strong Genetic Variation [10]
PARVA OTLKEWRY Strong Biomarker [4]
PBX1 OTORABGO Strong Biomarker [4]
PCDH15 OTU9C2EH Strong Biomarker [4]
PDYN OTEJ6430 Strong Biomarker [36]
PIWIL1 OT7CRGZ3 Strong Biomarker [4]
PMAIP1 OTXEE550 Strong Biomarker [4]
POLR1D OTOCZQNA Strong Biomarker [4]
PRPF4 OTK0XRQN Strong Biomarker [4]
QSOX1 OT4ZPK4P Strong Biomarker [4]
RAD51B OTCJVRMY Strong Biomarker [4]
RHBDD3 OTJ3OLC8 Strong Biomarker [4]
RTL6 OT9LG762 Strong Biomarker [4]
SAMD4A OT4MKCC8 Strong Biomarker [4]
SAR1A OTSSRVGV Strong Biomarker [37]
SEMA6D OTU0UAZS Strong Biomarker [4]
SYNE1 OTSBSLUH Strong Biomarker [4]
TBXT OTHCO2F0 Strong Genetic Variation [38]
TENM2 OTPLUYEF Strong Biomarker [4]
THSD4 OTXDBMDC Strong Biomarker [4]
TIAM2 OTPYIPT6 Strong Biomarker [4]
TMPRSS7 OTW938I4 Strong Biomarker [4]
TTC21B OTXXA87U Strong Biomarker [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 91 DOT(s)

References

1 Disease-associated polymorphisms within the conserved ECR1 enhancer differentially regulate the tissue-specific activity of the cannabinoid-1 receptor gene promoter; implications for cannabinoid pharmacogenetics.Hum Mutat. 2020 Jan;41(1):291-298. doi: 10.1002/humu.23931. Epub 2019 Nov 4.
2 Association of the DRD4 exon III and 5-HTTLPR VNTR polymorphisms with substance abuse in Jordanian Arab population.Gene. 2020 Apr 5;733:144267. doi: 10.1016/j.gene.2019.144267. Epub 2019 Dec 3.
3 Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent -Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction.J Am Chem Soc. 2018 Feb 14;140(6):2151-2164. doi: 10.1021/jacs.7b10965. Epub 2018 Jan 30.
4 Genome wide association for addiction: replicated results and comparisons of two analytic approaches.PLoS One. 2010 Jan 21;5(1):e8832. doi: 10.1371/journal.pone.0008832.
5 Altered neural cholinergic receptor systems in cocaine-addicted subjects.Neuropsychopharmacology. 2010 Jun;35(7):1485-99. doi: 10.1038/npp.2010.18. Epub 2010 Mar 10.
6 Low ethanol concentration alters CHRNA5 RNA levels during early human development. Reprod Toxicol. 2010 Nov;30(3):489-92. doi: 10.1016/j.reprotox.2010.04.011. Epub 2010 May 11.
7 Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia.Schizophr Res. 2008 Jan;98(1-3):129-38. doi: 10.1016/j.schres.2007.09.032. Epub 2007 Oct 26.
8 The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study.Ther Drug Monit. 2008 Jun;30(3):265-70. doi: 10.1097/FTD.0b013e31817721d6.
9 An Information Theoretical Study of the Epistasis Between the CNR1 1359 G/A Polymorphism and the Taq1A and Taq1B DRD2 Polymorphisms: Assessing the Susceptibility to Cannabis Addiction in a Turkish Population.J Mol Neurosci. 2016 Apr;58(4):456-60. doi: 10.1007/s12031-016-0721-z. Epub 2016 Jan 30.
10 Dopamine D3 receptor gene variants and substance abuse in schizophrenia.Mol Psychiatry. 1998 Jul;3(4):337-41. doi: 10.1038/sj.mp.4000411.
11 An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study.Behav Genet. 1998 Mar;28(2):75-82. doi: 10.1023/a:1021463722326.
12 Early-life adversity selectively impairs 2-GABA(A) receptor expression in the mouse nucleus accumbens and influences the behavioral effects of cocaine.Neuropharmacology. 2018 Oct;141:98-112. doi: 10.1016/j.neuropharm.2018.08.021. Epub 2018 Aug 21.
13 Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats.Neuropsychopharmacology. 2018 Dec;43(13):2615-2626. doi: 10.1038/s41386-018-0231-5. Epub 2018 Oct 3.
14 Context and topography determine the role of basolateral amygdala metabotropic glutamate receptor 5 in appetitive Pavlovian responding.Neuropsychopharmacology. 2019 Aug;44(9):1524-1533. doi: 10.1038/s41386-019-0335-6. Epub 2019 Feb 8.
15 Serotonin and drug reward: focus on 5-HT2C receptors.Eur J Pharmacol. 2003 Nov 7;480(1-3):151-62. doi: 10.1016/j.ejphar.2003.08.102.
16 Genetic modulation of plasma NPY stress response is suppressed in substance abuse: association with clinical outcomes.Psychoneuroendocrinology. 2012 Apr;37(4):554-64. doi: 10.1016/j.psyneuen.2011.08.005. Epub 2011 Sep 13.
17 Hypermethylation of the 1 opioid receptor promoter in Chinese heroin and methamphetamine addicts.Exp Ther Med. 2018 Sep;16(3):2392-2398. doi: 10.3892/etm.2018.6514. Epub 2018 Jul 24.
18 Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.J Am Chem Soc. 2016 Jun 1;138(21):6754-64. doi: 10.1021/jacs.6b00360. Epub 2016 May 18.
19 Genome-wide association study in bipolar patients stratified by co-morbidity.PLoS One. 2011;6(12):e28477. doi: 10.1371/journal.pone.0028477. Epub 2011 Dec 21.
20 Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder.Alcohol Clin Exp Res. 2006 Oct;30(10):1644-9. doi: 10.1111/j.1530-0277.2006.00215.x.
21 (AZI2)3'UTR Is a New SLC6A3 Downregulator Associated with an Epistatic Protection Against Substance Use Disorders.Mol Neurobiol. 2018 Jul;55(7):5611-5622. doi: 10.1007/s12035-017-0781-2. Epub 2017 Oct 5.
22 Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function.Biol Psychiatry. 2009 Jul 1;66(1):9-16. doi: 10.1016/j.biopsych.2008.10.047. Epub 2008 Dec 21.
23 The ankyrin-3 gene is associated with posttraumatic stress disorder and externalizing comorbidity.Psychoneuroendocrinology. 2013 Oct;38(10):2249-57. doi: 10.1016/j.psyneuen.2013.04.013. Epub 2013 Jun 21.
24 ASTN1 and alcohol dependence: family-based association analysis in multiplex alcohol dependence families.Am J Med Genet B Neuropsychiatr Genet. 2012 Jun;159B(4):445-55. doi: 10.1002/ajmg.b.32048. Epub 2012 Apr 9.
25 Burden of Substance Abuse-Related Admissions to the Medical ICU.Chest. 2020 Jan;157(1):61-66. doi: 10.1016/j.chest.2019.08.2180. Epub 2019 Sep 5.
26 Genetic background of extreme violent behavior.Mol Psychiatry. 2015 Jun;20(6):786-92. doi: 10.1038/mp.2014.130. Epub 2014 Oct 28.
27 Wellbeing and mental health amongst medical students in Jordan: a descriptive study.Int Rev Psychiatry. 2019 Nov-Dec;31(7-8):619-625. doi: 10.1080/09540261.2019.1670402. Epub 2019 Oct 3.
28 LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry.Arch Gen Psychiatry. 1983 Aug;40(8):877-83. doi: 10.1001/archpsyc.1983.01790070067008.
29 Gender-stratified gene and gene-treatment interactions in smoking cessation.Pharmacogenomics J. 2012 Dec;12(6):521-32. doi: 10.1038/tpj.2011.30. Epub 2011 Aug 2.
30 Trends In Substance Use And Related Disorders: Analysis of the Epidemiological Survey of Substance Abuse 1995 to 2018.Dtsch Arztebl Int. 2019 Sep 2;116(35-36):585-591. doi: 10.3238/arztebl.2019.0585.
31 Association analysis of GABRB3 promoter variants with heroin dependence.PLoS One. 2014 Jul 15;9(7):e102227. doi: 10.1371/journal.pone.0102227. eCollection 2014.
32 Association of a polymorphism in the Homer1 gene with cocaine dependence in an African American population. Psychiatr Genet. 2005 Dec;15(4):277-83. doi: 10.1097/00041444-200512000-00010.
33 NCS-1 is a regulator of calcium signaling in health and disease.Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt B):1660-1667. doi: 10.1016/j.bbamcr.2018.05.005. Epub 2018 May 8.
34 Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.PLoS One. 2019 Jun 26;14(6):e0218011. doi: 10.1371/journal.pone.0218011. eCollection 2019.
35 NrCAM in addiction vulnerability: positional cloning, drug-regulation, haplotype-specific expression, and altered drug reward in knockout mice. Neuropsychopharmacology. 2006 Mar;31(3):572-84. doi: 10.1038/sj.npp.1300855.
36 Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci Lett. 2006 May 29;400(1-2):158-62. doi: 10.1016/j.neulet.2006.02.038. Epub 2006 Mar 9.
37 Substance abuse-related admissions in a mixed Norwegian intensive care population.Acta Anaesthesiol Scand. 2020 Mar;64(3):329-337. doi: 10.1111/aas.13506. Epub 2019 Nov 29.
38 Prior Exposure to Intimate Partner Violence Associated With Less HIV Testing Among Young Women.J Interpers Violence. 2021 Mar;36(5-6):NP2848-NP2867. doi: 10.1177/0886260518768564. Epub 2018 Apr 13.